Unicycive Therapeutics, Inc.
UNCYHealthcareNASDAQBiotechnology · Last scanned Oct 26, 2026
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Unicycive Therapeutics, Inc. focuses on Biotechnology services and products. Unicycive Therapeutics, Inc., a clinical-stage biotechnology company, identifies, develops, and commercializes therapies for the treatment of kidney diseases in the United States. With a market capitalization of $106.6M, it sits in micro-cap territory. It develops oxylanthanum carbonate, a lanthanum-based phosphate binding agent, which is for the treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI-494, a nicotinamide ester derivative and a selective ATP-sensitive mitochondrial potassium channel activator, which is in Phase I clinical trial for the treatment of acute kidney injury and pre-clinical stage for the treatment of chronic kidney disease.
Market Cap
$106.6M
Beta
1.82
P/E (TTM)
—
P/E (Fwd)
2.31
EPS (TTM)
$-1.72
EPS (Fwd)
$1.69
ROE
-101.1%
ROA
-40.6%
Cash
$61.4M
Total Debt
$671,000
Free CF
-$12.7M
52W Change
-25.8%
Annual Financials
Cash vs Debt
Where UNCY stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, UNCY finished 42.36% below its 150-day moving average ($6.09) and 43.39% below its 200-day moving average ($6.20). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is UNCY overbought or oversold?
At the October 20, 2026 close, UNCY's RSI(14) was 20.9, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Unicycive Therapeutics, Inc. holds $61.4M in cash against $671K in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. Free cash flow is running at -$12.7M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -101.1% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has pulled back from $951K (2022) to $0 (2025), a 100% decline worth watching.
Unicycive Therapeutics, Inc.'s elevated beta suggests the stock experiences more pronounced price movements than the overall market, which increases both upside potential and downside risk. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. No single metric tells the full story. Reviewing UNCY's risk profile alongside its fundamentals and technical indicators provides a more complete picture.